Per 0.5 mL dose Diphtheria toxoid not <2 IU, tetanus toxoid not <20 IU, Bordetella pertussis antigens (pertussis toxoid 8 mcg, filamentous haemagglutinin 8 mcg, pertactin 2.5 mcg)
Indications/Uses
Booster vaccination against diphtheria, tetanus & pertussis for individuals from ≥4 yr. Passive protection against pertussis in early infancy following maternal immunization during pregnancy.
A single 0.5 mL dose by deep IM inj preferably in the deltoid region. Can be administered to pregnant women between 27 & 36 wk of pregnancy in accordance w/ official recommendations.
View Boostrix overdosage for action to be taken in the event of an overdose.
Contraindications
Hypersensitivity to any component of Boostrix or after previous administration of diphtheria, tetanus or pertussis vaccines. Encephalopathy of unknown etiology occurring w/in 7 days following previous vaccination w/ pertussis-containing vaccine. Transient thrombocytopenia or neurological complications following an earlier immunization against diphtheria &/or tetanus.
Do not administer IV. Postpone administration in patients w/ acute severe febrile illness. Temp ≥40°C; collapse or shock-like state; persistent, inconsolable crying lasting ≥3 hr, occurring w/in 48 hr of vaccination or convulsions w/ or w/o fever, occurring w/in 3 days of vaccination. Progressive neurological disorders including infantile spasms, uncontrolled epilepsy or progressive encephalopathy. Thrombocytopenia or bleeding disorders. Immunosuppressed patients. Syncope (fainting) may occur. A protective immune response may not be elicited in all vaccinees. Can be used between 27 & 36 wk of pregnancy. Lactation.
If to be given at the same time as other vaccines or Ig, the products should be administered at different sites. Adequate response may not be achieved w/ immunosuppressive therapy & patients w/ immunodeficiency.
Sign Out
e31c9196-e324-468c-bbc8-a8b900f73d72.GIF)
